Friday, January 29, 2021 9:37:05 AM
ProPhase Labs Announces Opening of Large CLIA Lab Covid Testing Facility in Garden City, New York
ProPhase Labs, Inc.
Updated Fri, January 29, 2021, 8:52 AM
More content below
- Total Company Processing Capacity On Track to Reach 60,000 Tests Per Day –
GARDEN CITY, NY, Jan. 29, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, announced today the opening of its 25,000 square foot facility in Garden City, New York. The new lab features state-of-the-art technology and offers a wide range of laboratory testing services for diagnosis, screening and evaluation of diseases, including COVID-19 and Respiratory Pathogen Panel Molecular tests.
The lab features the latest Thermo Fisher Scientific lab equipment and employs approximately 75 technical staff. The Company will add additional technical staff to meet client needs as the lab continues to ramp-up. The lab is already processing COVID-19 tests, and the Company plans to expand lab capacity to be able to process up to 50,000 COVID-19 tests per day by the end of the current fiscal quarter. The technology embedded in the new lab will enable the Company to offer highly competitive pricing to customers and to deliver test results, in most cases, within 24 hours. The lab also will be operating and processing tests seven days a week.
“We are exceptionally proud of our team’s rapid buildout of the new lab and successful onboarding of a world-class technical staff for the new facility. Our strategic rollout of CLIA Labs is proceeding exactly as planned,” said Ted Karkus, CEO of ProPhase Labs. “Our two labs, Garden City, New York and Old Bridge, New Jersey, working in tandem, are expected to enable us to process 60,000 tests per day. In addition to COVID-19 testing, we are looking to diversify into other areas of high margin diagnostic molecular testing,” explained Karkus.
ProPhase Diagnostics Update
ProPhase Diagnostics, Inc., a wholly-owned subsidiary of the Company, which was formed to aggregate medical testing business opportunities for the Company, continues to expand its lab capabilities and testing capacity by expanding its physical presence to include the new Garden City, New York location and adding several key new hires to its team.
Steve Kamalic, Chief Operating Officer - ProPhase Diagnostics
Steve Kamalic is a veteran operations executive with decades of experience building and growing lab processing units. At ProPhase Diagnostics, Steve will be responsible for ensuring the company meets its stated goal of 60,000 tests per day between its Garden City, New York lab and Old Bridge, New Jersey lab. Prior to joining ProPhase Diagnostics, Steve served as Chief Operating Officer and Sales Director at a substantial regional lab. He oversaw a laboratory business that significantly grew its annual revenues. He has worked at several startups and has a vision for growth and expansion. Steve holds an AAS in medical technology and a BS in Health Administration.
Sergio Miralles, Chief Information Officer - ProPhase Diagnostics
Sergio Miralles is an experienced IT Leader, with over 12 years of experience in enterprise level Cybersecurity, Infrastructure, and Architecture. At ProPhase Diagnostics, Sergio will be responsible for ensuring a complete end-to-end technology solution that links its lab customers’ patient data via interface to efficiently process and report results. Previously, Miralles founded and led a successful IT consulting firm overseeing 18 IT consultants. For the last 5 years, his primary focus has been on the medical, lab, and diagnostics business. Sergio holds several certifications from Cisco, ISC2, and CompTIA.
Carlos D. Brewster, Head of Molecular Lab Testing - ProPhase Diagnostics
Carlos Brewster has over 18 years of experience in the Molecular Biology field, which started with an internship with the Federal Government in Washington DC. Carlos’ current responsibilities encompass assay design, validation, implementation and training. Prior to joining ProPhase Diagnostics, he served as a Research and Development Specialist. Since the onset of the pandemic he has received several FDA Emergency Use Authorizations for the COVID-19 Assay, which is now being utilized within the industry by numerous laboratories and has generated millions of dollars in revenue. Carlos holds a Bachelor of Science in Biology. He also holds a New York State License as a Clinical Laboratory Technologist.
Karkus added: “We are privileged to welcome these three experts in their respective fields to the ProPhase team. Steve has decades of experience building out lab processing, and his knowledge will be of great value as we continue our expansion efforts. Sergio will help us to bridge the gap between lab processing and the more difficult challenge of linking to customers via an interface to efficiently upload patient data and report results in a timely and efficient manner. Carlos was instrumental in the purchase, acquisition and installation of the latest Thermo Fisher equipment for our New Jersey lab and our new New York facility. Carlos’ focus will now be on helping us to expand our overall testing capacity and achieve our goal of hitting 60,000 tests per day. Together, the leadership team at ProPhase Diagnostics is coming together, and I have never been more confident in their ability to position us as a leading testing provider.”
About ProPhase Labs
ProPhase Labs (NASDAQ: PRPH) is a diversified medical science and technology company with deep experience with OTC consumer healthcare products and dietary supplements. The Company is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States. This includes the development and marketing of dietary supplements under the TK Supplements® brand. The Company’s subsidiary, ProPhase Diagnostics, Inc. (“ProPhase Diagnostics”), offers COVID-19 and other Respiratory Pathogen Panel (RPP) Molecular tests. The Company also continues to actively pursue strategic investments and acquisition opportunities for other companies, technologies and products. For more information visit us at www.ProPhaseLabs.com.
Recent PRPH News
- PROPHASE LABS INC. TO PRESENT FIRST QUARTER 2024 FINANCIAL RESULTS ON MAY 9 • GlobeNewswire Inc. • 05/02/2024 12:00:00 PM
- ProPhase Labs to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024 • GlobeNewswire Inc. • 04/25/2024 12:00:00 PM
- ProPhase Labs Unveils Project ZenQ-AI • GlobeNewswire Inc. • 04/16/2024 12:00:00 PM
- ProPhase Labs Seeks to Transform Esophageal Cancer Detection and Management with Launch of its BE-Smart Test in H2 2024 • GlobeNewswire Inc. • 04/10/2024 12:00:00 PM
- ProPhase Labs Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/02/2024 01:00:00 AM
- ProPhase Labs Announces Financial Results for the Year Ended December 31, 2023 and Significant Progress in Its Strategic Initiatives • GlobeNewswire Inc. • 03/15/2024 12:00:00 PM
- PROPHASE LABS TO PRESENT 2023 YEAR END FINANCIAL RESULTS ON MARCH 15, 2024 • GlobeNewswire Inc. • 03/08/2024 01:00:00 PM
- ProPhase Labs Announces Significant Progress in BE-Smart Esophageal Cancer Test Development USPTO grants additional broad patents for BE-SMART • GlobeNewswire Inc. • 02/20/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:05:49 PM
- ProPhase Labs Announces Preliminary Positive Results for Dietary Supplement Equivir • GlobeNewswire Inc. • 02/14/2024 01:00:00 PM
- ProPhase Labs Ushers in New Genomics Era with Jason Karkus at the Helm of Nebula Genomics • GlobeNewswire Inc. • 01/30/2024 01:00:00 PM
- Pharmaloz Manufacturing Accelerates Expansion, Improves Pricing, Boosts Profitability and Secures New Contracts • GlobeNewswire Inc. • 01/23/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 01:05:18 PM
- ProPhase poised to ramp up growth at Pharmaloz and Nebula Genomics in 2024 • GlobeNewswire Inc. • 01/04/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:04:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 01:00:39 PM
- ProPhase Labs Announces Financial Results for the Three Months Ended September 30, 2023 • GlobeNewswire Inc. • 11/09/2023 01:00:00 PM
- ProPhase Labs to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 9, 2023 at 11:00 a.m. Eastern Time • GlobeNewswire Inc. • 11/02/2023 12:00:00 PM
- ProPhase Labs Announces Substantial Growth Expectations for Pharmaloz Manufacturing Subsidiary due to Skyrocketing Demand for Pharmaloz Output. • GlobeNewswire Inc. • 10/17/2023 12:00:00 PM
- DSS Inc. Issues Letter to Shareholders • GlobeNewswire Inc. • 10/12/2023 12:25:00 PM
- ProPhase Labs to Present at The ThinkEquity Conference • GlobeNewswire Inc. • 10/12/2023 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2023 08:10:43 PM
- ProPhase Labs Announces Updated Conference Call Dial-in Information for Thursday August 10, 2023 at 11:00 a.m. Eastern Time for Second Quarter 2023 Financial Results Call. • GlobeNewswire Inc. • 08/10/2023 02:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 12:00:15 PM
- ProPhase Labs Announces Financial Results for the Three Months Ended June 30, 2023 • GlobeNewswire Inc. • 08/10/2023 12:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM